{"id":"https://openalex.org/W2103444528","doi":null,"title":"Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.","display_name":"Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.","publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W2103444528","mag":"2103444528","pmid":"https://pubmed.ncbi.nlm.nih.gov/22393954"},"language":"en","primary_location":{"id":"pmid:22393954","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22393954","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Asian Pacific journal of cancer prevention : APJCP","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019102566","display_name":"Xinji Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I177933477","display_name":"Second Military Medical University","ror":"https://ror.org/04tavpn47","country_code":"CN","type":"education","lineage":["https://openalex.org/I177933477"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xinji Zhang","raw_affiliation_strings":["Department of Health Statistics, Second Military Medical University, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Statistics, Second Military Medical University, Shanghai, China","institution_ids":["https://openalex.org/I177933477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029498134","display_name":"Yingyi Qin","orcid":"https://orcid.org/0000-0002-3340-3776","observed_orcids":["https://orcid.org/0000-0002-3340-3776"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yingyi Qin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100423995","display_name":"Hui Li","orcid":"https://orcid.org/0000-0003-4759-1779","observed_orcids":["https://orcid.org/0000-0003-4759-1779","https://orcid.org/0009-0001-6164-5393"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hui Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102788474","display_name":"Chong Bai","orcid":"https://orcid.org/0000-0002-9260-7007","observed_orcids":["https://orcid.org/0000-0002-9260-7007"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chong Bai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Tianyi Zhu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tianyi Zhu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070391038","display_name":"Jinfang Xu","orcid":"https://orcid.org/0000-0002-6642-8152","observed_orcids":["https://orcid.org/0000-0002-6642-8152"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jinfang Xu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008103342","display_name":"Cheng Wu","orcid":"https://orcid.org/0000-0003-2707-6163","observed_orcids":["https://orcid.org/0000-0003-2707-6163"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cheng Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101770917","display_name":"Mengjie Wu","orcid":"https://orcid.org/0000-0001-8410-1906","observed_orcids":["https://orcid.org/0000-0001-8410-1906"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mengjie Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011266160","display_name":"Chaoxiang Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chaoxiang Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033893468","display_name":"Hualing Song","orcid":"https://orcid.org/0000-0002-0589-2904","observed_orcids":["https://orcid.org/0000-0002-0589-2904"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hualing Song","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031753073","display_name":"Lixin Wei","orcid":"https://orcid.org/0000-0002-9526-5348","observed_orcids":["https://orcid.org/0000-0002-9526-5348"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lixin Wei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5027674411","display_name":"Jia He","orcid":"https://orcid.org/0000-0002-2338-9501","observed_orcids":["https://orcid.org/0000-0002-2338-9501","https://orcid.org/0009-0006-9400-8952"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jia He","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.2402,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.80793638,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"12","issue":"11","first_page":"2857","last_page":"63"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vandetanib","display_name":"vandetanib","score":1.0},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.953000009059906},{"id":"https://openalex.org/keywords/vegfr-tyrosine-kinase-inhibitors","display_name":"VEGFR inhibitors","score":0.8259999752044678},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.9959999918937683},{"id":"https://openalex.org/keywords/dual-tyrosine-kinase-inhibitor","display_name":"dual tyrosine kinase inhibitor","score":0.718999981880188},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9509999752044678},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9409999847412109},{"id":"https://openalex.org/keywords/objective-response","display_name":"objective response","score":0.8889999985694885},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.7950000166893005},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6159999966621399},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.5770000219345093}],"concepts":[{"id":"https://openalex.org/C2780333294","wikidata":"https://www.wikidata.org/wiki/Q7914515","display_name":"Vandetanib","level":4,"score":0.9966959953308105},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8017511367797852},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6523618698120117},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6384105086326599},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5572938323020935},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5134040117263794},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4908009469509125},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.44556957483291626},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4434100091457367},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.4196019768714905},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34337419271469116},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.18287158012390137},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11718609929084778},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09109559655189514},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.056436628103256226},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:22393954","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22393954","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Asian Pacific journal of cancer prevention : APJCP","raw_type":"Journal Article"},{"id":"mag:2103444528","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22393954","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W71228264","https://openalex.org/W1596902544","https://openalex.org/W1986215651","https://openalex.org/W1996761484","https://openalex.org/W1998482951","https://openalex.org/W2004350020","https://openalex.org/W2033048942","https://openalex.org/W2075642745","https://openalex.org/W2101995865","https://openalex.org/W2102590541","https://openalex.org/W2107328434","https://openalex.org/W2107666024","https://openalex.org/W2110835998","https://openalex.org/W2114940128","https://openalex.org/W2115078104","https://openalex.org/W2118559000","https://openalex.org/W2122553809","https://openalex.org/W2124464299","https://openalex.org/W2125212831","https://openalex.org/W2125435699","https://openalex.org/W2125916043","https://openalex.org/W2126655764","https://openalex.org/W2127101185","https://openalex.org/W2127809030","https://openalex.org/W2132157071","https://openalex.org/W2138297714","https://openalex.org/W2145835533","https://openalex.org/W2147289344","https://openalex.org/W2150335765","https://openalex.org/W2152755651","https://openalex.org/W2162724777","https://openalex.org/W2164093802","https://openalex.org/W2433114596","https://openalex.org/W2537925245"],"related_works":["https://openalex.org/W2285006718","https://openalex.org/W2096537545","https://openalex.org/W2009874537","https://openalex.org/W1970779231","https://openalex.org/W2114940128","https://openalex.org/W1978111504","https://openalex.org/W2433114596","https://openalex.org/W2003158975","https://openalex.org/W2107666024","https://openalex.org/W2124464299"],"abstract_inverted_index":{"BACKGROUND:":[0],"Vandetanib,":[1,197],"an":[2],"oral":[3],"inhibitor":[4],"of":[5,23,215],"vascular":[6],"endothelial":[7],"growth":[8,13],"factor":[9,14],"receptor":[10,15],"and":[11,35,41,48,70,104,107,180,205],"epidermal":[12],"signaling,":[16],"has":[17],"attracted":[18],"wide":[19],"interest":[20],"in":[21,80,112,136,164,183,212,238],"treatment":[22,214],"advanced":[24,52,216],"non-small-cell":[25],"lung":[26],"cancer":[27],"(NSCLC).":[28],"We":[29],"aimed":[30],"to":[31],"assess":[32],"its":[33],"efficacy":[34,228],"safety":[36],"via":[37],"a":[38,89,105,133],"systematic":[39],"review":[40],"meta-analysis.":[42],"METHODS:":[43],"Trials":[44],"comparing":[45],"vandetanib-based":[46],"therapy":[47,50],"non-vandetanib":[49],"for":[51,92],"NSCLC":[53],"were":[54,58,78],"identified.":[55],"Endpoints":[56],"evaluated":[57],"progression-free":[59],"survival":[60,63],"(PFS),":[61],"overall":[62],"(OS),":[64],"objective":[65],"tumor":[66],"response":[67],"rate":[68],"(ORR),":[69],"toxicity.":[71],"RESULTS:":[72],"Seven":[73],"trials":[74],"including":[75],"4,492":[76],"patients":[77],"included":[79],"the":[81,170,213,239],"analysis.":[82],"As":[83,218],"compared":[84,199,219],"with":[85,155,166,191,200,220],"placebo,":[86,201],"vandetanib":[87,151,179,223,240],"yielded":[88],"clear":[90],"benefit":[91],"ORR":[93,185,204],"(odds":[94],"ratio":[95,115],"(OR)":[96],"=":[97,117,139,145],"2.04;":[98],"95%":[99,119,141],"CI,":[100,120,142],"1.60-2.61;":[101],"P":[102,123,144],"<0.001),":[103],"clinically":[106],"statistically":[108,175],"significant":[109,134,176],"25%":[110],"improvement":[111,135],"PFS":[113],"(hazard":[114],"(HR)":[116],"0.75;":[118],"0.66-":[121],"0.85;":[122],"<":[124],"0.001).":[125],"However,":[126],"these":[127],"benefits":[128],"did":[129],"not":[130,209,225],"translate":[131],"into":[132],"OS":[137,211],"(HR":[138],"0.95;":[140],"0.88-1.04;":[143],"0.291).":[146],"Subgroup":[147],"analyses":[148],"showed":[149],"that":[150],"100mg/d":[152],"was":[153,189],"associated":[154,190],"greater":[156,234,237],"antitumor":[157],"activity":[158],"than":[159],"300":[160],"mg/d":[161],"when":[162],"given":[163],"combination":[165],"chemotherapy.":[167],"In":[168],"addition,":[169],"pooled":[171],"results":[172],"demonstrated":[173],"no":[174],"difference":[177],"between":[178],"single-targeted":[181,221],"agents":[182],"PFS,":[184,206],"or":[186,233],"OS.":[187],"Vandetanib":[188],"more":[192],"frequent":[193],"adverse":[194],"events.":[195],"CONCLUSIONS:":[196],"as":[198],"significantly":[202],"increases":[203],"but":[207],"does":[208,224],"improve":[210],"NSCLC.":[217],"agent,":[222],"provide":[226],"any":[227],"advantage.":[229],"Furthermore":[230],"grade":[231],"3":[232],"toxicity":[235],"proved":[236],"arm.":[241]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}